0000899243-22-021981.txt : 20220610 0000899243-22-021981.hdr.sgml : 20220610 20220610174021 ACCESSION NUMBER: 0000899243-22-021981 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220609 FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gaster Richard CENTRAL INDEX KEY: 0001866026 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 221010057 MAIL ADDRESS: STREET 1: C/O ELEVATION ONCOLOGY, INC. STREET 2: 888 SEVENTH AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-09 0 0001851194 Ventyx Biosciences, Inc. VTYX 0001866026 Gaster Richard C/O VENTYX BIOSCIENCES, INC. 662 ENCINITAS BLVD, SUITE 250 ENCINITAS CA 92024 1 0 0 0 Stock Option (right to buy) 16.54 2022-06-09 4 A 0 13301 0.00 A 2032-06-09 Common Stock 13301 13301 D The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date. Dr. Gaster is a partner of venBio Global Strategic GP III, L.P. and is a member of the board of directors of the Issuer. These options are held by Dr. Gaster for the benefit of venBio Global Strategic Fund III, L.P. ("venBio III"). Pursuant to policies of venBio Partners, the manager of venBio III, with respect to director compensation, upon the exercise of these options and sale of the underlying securities, the proceeds will be remitted to venBio III. Dr. Gaster disclaims beneficial ownership over the shares underlying the options held for the benefit of venBio III, and the filing of this Form 4 shall not be deemed an admission of beneficial ownership for purposes of Section 16 of the Securities and Exchange Act of 1934 or any other purpose. /s/ Christopher Krueger, as Attorney-in-Fact 2022-06-10